Replies to post #59321 on Anavex Life Sciences Corp (AVXL)

[joshalex5]

I believe so also.

[ClosetInvestor]

I'm confused by this post. Is this a copy and paste from the YMB? And is this a quote from someone with biotech experience or just a normal investor?

There is one huge difference between TauRX and AVXL: TauRX has completed a large, double-blind, phase 2 with 321 patients. The results can be reviewed here: http://taurx.com/phase-2.html. I'm no stats expert, but the results look good. The drug had absorption issues so it was redeveloped and that new drug is now in a phase 3.

What I'm getting at is this: to say that AVXL should be valued at 3-4x TauRX (if they went public) is completely insane. I'm long AVXL but positive phase 3, double-blind, placebo trial results are needed for AVXL to be valued at $9-12 billion dollars. AVXL isn't completely undervalued at this point because the market wants to see solid data, which takes time to get. If you look across the biotech sector, companies are being valued much lower than they were in 2015 and prior. Companies will have to start getting solid phase 2/3 data before evaluations start jumping into the billions, IMO.

Be patient, 2-73 will get there.

[hessmessinc]

It seems that TauRX is going to make it to market before we will...which kind of puts a damper on our success...